Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Operations: 2020-2024

Historic Cash from Operations for Entrada Therapeutics (TRDA) over the last 5 years, with Dec 2024 value amounting to -$41.6 million.

  • Entrada Therapeutics' Cash from Operations fell 16.68% to -$28.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$127.9 million, marking a year-over-year decrease of 815.96%. This contributed to the annual value of -$41.6 million for FY2024, which is 129.73% down from last year.
  • Entrada Therapeutics' Cash from Operations amounted to -$41.6 million in FY2024, which was down 129.73% from $139.8 million recorded in FY2023.
  • Over the past 5 years, Entrada Therapeutics' Cash from Operations peaked at $139.8 million during FY2023, and registered a low of -$93.8 million during FY2022.
  • Moreover, its 3-year median value for Cash from Operations was -$41.6 million (2024), whereas its average is $1.5 million.
  • As far as peak fluctuations go, Entrada Therapeutics' Cash from Operations soared by 249.07% in 2023, and later plummeted by 129.73% in 2024.
  • Over the past 5 years, Entrada Therapeutics' Cash from Operations (Yearly) stood at -$25.6 million in 2020, then plummeted by 98.91% to -$50.9 million in 2021, then tumbled by 84.39% to -$93.8 million in 2022, then soared by 249.07% to $139.8 million in 2023, then slumped by 129.73% to -$41.6 million in 2024.